BACKGROUNDTo investigate the relationship between immune status and rubella virus (RV) infection of central nervous system (CNS).

METHODSBALB/c mice were given dexamethaxone and cytoxan before RV JR23 strain infection. Immune functions and RV invasion to CNS were assayed at 21 days postinfection via abdominal cavity and their relationship was analyzed.

RESULTST cell functions of cytoxan group were obviously worse than those of other groups (P <0.05) by MTT method. Infection rates of dexamethaxone and cytoxan and the group without any intervention were 60%, 90% and 50% (P >0.05), respectively. Cellular immune functions of the mice with CNS infection were obviously worse than those of the mice without CNS infection (P <0.001). Specific antibodies (Ab) were assayed in all groups with ELISA and the results showed that there were no significant differences among groups (P >0.05), neither between the groups with and without CNS infections.

CONCLUSIONSRV infection of CNS may relate to cellular immune status before specific antibody was produced in the body.

Animals ; Antibody Specificity ; Central Nervous System Infections ; immunology ; virology ; Female ; Immunity, Cellular ; Male ; Mice ; Mice, Inbred BALB C ; Rubella ; immunology ; Rubella virus ; immunology ; T-Lymphocytes ; immunology

We measured the degree of immunity of 326 Korean children to rubella virus by enzyme-linked immunosorbent assy (ELISA). They were admitted to Pediatrics Unit of Yonsei Medical Center between April and July, 1980 with various illnesses excluding rubella disease. Among the 326 tested, 172 cases gave a positive titer of antibodies (mainly, IgG and IgM antibodies) and 127 had IgG antibody against rubella virus antigen. These represented 52.8% and 39.0%, respectively, of the total number of children tested. There was no significant difference in the rate of positivity between sex, but the positive rate increased as the age increased. The antobody titers of positive individuals to rubella virus were higher among the older children. Results and a brief outline of the ELISA method for serodiagnosis of rubella in clinical use will be discussed.
Adolescent ; Age Factors ; Antibodies, Viral/analysis* ; Child ; Child, Preschool ; Enzyme-Linked Immunosorbent Assay* ; Female ; Human ; Immunoenzyme Techniques* ; Infant ; Infant, Newborn ; Korea ; Male ; Rubella/immunology ; Rubella virus/immunology*

Adult ; Antibodies, Viral ; blood ; China ; epidemiology ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Immunoglobulin G ; blood ; Rubella ; epidemiology ; Rubella virus ; immunology ; isolation & purification ; Seroepidemiologic Studies

OBJECTIVETo evaluate the efficacy of the interferon alpha-2b nasal spray in prevention of rubella and measles virus infections.

METHODSThe properly selected volunteer groups have been divided into interferon alpha-2b experimental and control group. The experimental group received interferon alpha-2b treatment by nasal spray for 2 days before the immunization, then both groups were challenged with rubella and measles attenuated live vaccine respectively through nasal spray. The sera from pre-immunization and 21 and 28 days after immunization were collected to test the IgG antibody titers. The influence on the viral antibody titer reflects the viral preventive effect by interferon alpha-2b.

RESULTSThe antibody titer difference of measles virus between experimental and control group was 1.26 (21 day) and 2.96 (28 day), there were statistically difference between them; the difference of rubella virus was 0.95 (21 day) and 0.37 (28 day), but there were no statistically differences found.

CONCLUSIONThe preliminary results showed that the interferon alpha-2b can be used as prevention method for measles and rubella viral infections.

Administration, Intranasal ; Adult ; Antibodies, Viral ; blood ; Antiviral Agents ; administration & dosage ; therapeutic use ; Female ; Humans ; Interferon-alpha ; administration & dosage ; therapeutic use ; Male ; Measles ; immunology ; prevention & control ; virology ; Measles Vaccine ; immunology ; therapeutic use ; Measles virus ; drug effects ; immunology ; Recombinant Proteins ; Rubella ; immunology ; prevention & control ; virology ; Rubella Vaccine ; immunology ; therapeutic use ; Rubella virus ; drug effects ; immunology ; Treatment Outcome ; Vaccination ; methods ; Vaccines, Attenuated ; immunology ; therapeutic use ; Young Adult

BACKGROUND: The dramatic increase in use of the IgG test for toxoplasma, rubella, cytomegalovirus (CMV), and herpes simplex virus (HSV) [TORCH] has led to the requirement for a high-efficiency method that can be used in the clinical laboratory. This study aimed to compare the results of BGI-Array ELISA TORCH IgG (BGI-GBI, China) screening method to those of Virion/Serion TORCH IgG ELISA (Virion/Serion, Germany). METHODS: Serum specimens (n=400) submitted for routine IgG testing by Virion/Serion ELISA were also tested using the BGI-Array ELISA method. The agreements of these two kinds of method were analyzed by kappa-coefficients calculation. RESULTS: Following repeat testing, the BGI-Array ELISA TORCH IgG assays demonstrated agreements of 99.5% (398/400 specimens), 98% (392/400 specimens), 99% (396/400 specimens), and 99.5% (398/400 specimens), respectively. The BGI-Array ELISA IgG assays provided results comparable to Virion/Serion ELISA results, with kappa-coefficients showing near-perfect agreement for the HSV (kappa=0.87), rubella (kappa=0.92) and CMV (kappa=0.93) and substantial agreement for the toxoplasma (kappa=0.80) IgG assays. The use of the BGI-Array ELISA TORCH IgG assays could reduce the turnaround time (1.5 hr vs. 5 hr by Virion/Serion ELISA for 100 specimens) and were easy to use. CONCLUSIONS: BGI-Array ELISA TORCH IgG shows a good agreement with Virion/Serion ELISA methods and is suitable for clinical application.
Antibodies, Viral/blood ; Cytomegalovirus/immunology/*metabolism ; *Enzyme-Linked Immunosorbent Assay ; Humans ; Immunoglobulin G/*analysis/blood ; Protozoan Infections/diagnosis ; Reagent Kits, Diagnostic ; Rubella virus/immunology/*metabolism ; Sensitivity and Specificity ; Simplexvirus/immunology/*metabolism ; Toxoplasma/immunology/*metabolism ; Virion/*immunology/metabolism ; Virus Diseases/diagnosis

OBJECTIVETo explore the therapeutic effect and acting mechanism of Huanglan Granule (HLG) on rubella virus (RuV).

METHODSSixty patients with positive RuV-IgM were randomly assigned to two groups equally, the treatment group was medicated by HLG (one dosage per day, containing milkvetch root, isatis root and basket fern, each 30 g), while the control group by ribavirin (0.2 g, three times per day) for 20 days. The negative conversion rate of RuV-IgM and the serum levels of interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-alpha) were observed before and after treatment. Moreover, the in vitro inhibitory activity of HLG against RuV Gos line on cultured Vero cells was determined by cytopathic inhibition method.

RESULTSThe difference of negative conversion rate between the two groups after one course treatment was significant (86.7% vs 63.3%, P <0.05). However, it turned to insignificant after two courses of treatment (100% vs 86.7%, P >0.05). The serum level of IL-2 was lower and TNF-alpha was higher significantly in patients with positive RuV-IgM as compared with the normal range, and the two indexes returned to the normal range rapidly after HLG treatment. In vitro study showed that the inhibitory effect of HLG on RuV caused cellular change was evident.

CONCLUSIONHLG has obvious inhibitory effect on RuV, both in vitro and in vivo, it can also raise the immunity of organism and thus it serves as a safe and effective Chinese medicine for treatment of active RuV infection.

Adult ; Antibodies, Viral ; blood ; Drugs, Chinese Herbal ; administration & dosage ; Female ; Humans ; Immunoglobulin M ; blood ; Interleukin-2 ; blood ; Rubella ; blood ; drug therapy ; immunology ; virology ; Rubella virus ; drug effects ; immunology ; Tumor Necrosis Factor-alpha ; blood ; Young Adult

OBJECTIVETo construct a recombinant plasmid vector of the RV specific fragment for expressing the specific fragment of RV E1 protein.

METHODSRNA of the RV attenuated live vaccine Wistar RA27/3 strain was extracted and reversely transcribed. The specific fragment of the E1 gene was amplified and the PCR products cloned in the vector pGEX-2T after purification. Positive clones were selected and identified by two-enzyme digestion and sequence analysis.

RESULTSA 330 bp target fragment was successfully cloned, and the sequence of the recombinant plasmid was consistent with the original sequence.

CONCLUSIONSuccessful cloning of the RV El specific fragment and the construction of the recombinant plasmid have laid a foundation for further expressing the recombinant protein.

Base Sequence ; Cloning, Molecular ; Gene Expression ; Genetic Vectors ; Molecular Sequence Data ; Plasmids ; RNA, Viral ; Reverse Transcriptase Polymerase Chain Reaction ; Rubella virus ; genetics ; immunology ; Viral Envelope Proteins ; genetics ; immunology

Rubella virus (RV), one of pathogens in TORCH syndrome, can lead to anisotropy of the fetus, and therefore it is of great significance to screen RV infection among women at child-bearing age. At the present, the screening of RV infection is mainly based on the ELISA method, the specificity of RV antigens is very important for ELISA tests. The antigenicity of RV is closely associated with its structural proteins, including capsid protein C, and envelope glycoproteins E1 and E2, which are important surface antigens of RV. This paper reviews the advances in the studies on the structure features, immunogenicity and recombinant proteins of the three structural proteins.
Antibodies, Viral ; analysis ; Enzyme-Linked Immunosorbent Assay ; Recombinant Proteins ; immunology ; Rubella virus ; genetics ; immunology ; Viral Core Proteins ; genetics ; immunology ; Viral Envelope Proteins ; genetics ; immunology ; Viral Structural Proteins ; genetics ; immunology

INTRODUCTIONMeasles, mumps and rubella (MMR) are viral infections causing significant mortality and morbidity for which effective and safe vaccines are available. The safety, reactogenicity and immunogenicity of a combined MMR vaccine when administered to healthy Singaporean children were evaluated in this study.

MATERIALS AND METHODSA total of 150 children aged 12 to 18 months were vaccinated in this open, single-group, single-centre study [209762/147]. Solicited local and general symptoms reported within 4 days of vaccination and fever, parotid/salivary gland swelling and signs of meningism in the 43 days following vaccination were recorded using diary cards. Serious adverse events occurring during the study period were monitored. Immunogenicity was assessed at 42 days post-vaccination.

RESULTSRedness (8.7%) and pain (7.2%) at injection site were the most commonly reported solicited local symptoms during the 4-day follow-up period after vaccination. Percentage of subjects reporting drowsiness, irritability and loss of appetite during the 4-day follow-up after vaccination was 7.2%, 8% and 7.2%, respectively. None of the solicited symptoms reported during the 4-day follow-up period was of grade "3" intensity. Fever (42.8%) was the most commonly reported solicited general symptom, with 5.1% of the children reporting fever >39.0 degrees C (axillary). No serious adverse events considered to be related to vaccination were reported. Seroconversion rates were 100% for measles and rubella antibodies and 98.1% for mumps antibodies.

CONCLUSIONSGlaxoSmithKline Biologicals' MMR vaccine was shown to be well tolerated and highly immunogenic when used in Singaporean children 12 to 18 months of age.

Female ; Health Status ; Humans ; Infant ; Infant Welfare ; Male ; Measles ; prevention & control ; Measles-Mumps-Rubella Vaccine ; adverse effects ; immunology ; Mumps ; prevention & control ; Mumps virus ; Prospective Studies ; Rubella ; prevention & control ; Singapore

OBJECTIVETo express the rubella virus E1-374 glycoprotein in Pichia pastoris and study the immunogenecity of the recombinant protein.

METHODSThe cDNA of protein E1-374 was cloned into the expression vector pGAPZalphaA and transformed into Pichia pastoris GS115 cells by electrotransfection. The expressed protein was confirmed by indirect immunofluorescence and demonstrated immunoreactivity by Western Blot. Rubella virus IgG antibody was assayed with ELISA after mice were inmmunized by E1-374 glycoprotein.

RESULTSSDS-PAGE analysis and Western Blot analysis of E1-374 protein revealed this protein to be 46.89 x 10(3). Antiserum (1:100) and E1-374 (5.5 microg/ml) was chosen for ELISA optimization. The intra-assay coefficient of variation for the ELISA was 0.36%-12.45%.

CONCLUSIONProtein E1-374 was highly expressed in Pichia pastoris cells, and it was a good choice to prepare rubella virus recombinant protein vaccines.

Animals ; Enzyme-Linked Immunosorbent Assay ; Female ; Gene Expression ; Humans ; Mice ; Mice, Inbred BALB C ; Pichia ; genetics ; metabolism ; Recombinant Proteins ; genetics ; immunology ; Rubella virus ; genetics ; immunology ; Viral Envelope Proteins ; genetics ; immunology